Belarus to Produce Insulin Analogs Using Russian Tech by 2026
Belarus is set to produce insulin analogs using Russian technology, with 'Belmedpreparations' leading the effort under a licensing agreement with 'Geropharm'. The localized insulin, expected to be ready by 2026, will be marketed under the names 'RinGluzin', 'RinGlar', and 'RinGlar 300'.
The production will initially focus on 100 and 300 IU doses of insulin glulisine and glargine. The project, which has raised no public eyebrows about its main sponsor or financier, is expected to boost local pharmaceutical capabilities. The use of Russian technology is a notable aspect of this venture.
The start of production is slated for the near future, with completion expected by 2026. This timeline allows for the necessary setup and training to ensure high-quality output.
Belarus's insulin production using Russian technology is poised to enhance local healthcare provisions. The localized insulin, marketed under the 'Rin' brand, will provide much-needed supplies. Despite the lack of public information on the main sponsor or financier, the project's progress is closely monitored.
